| Filed On | Filing |
|---|---|
| 03 Mar 2026 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) |
| 06 Jun 2019 | 8-K/A: Financial Statements and Exhibits |
| 24 Dec 2018 | 8-K/A: Entry into a Material Definitive Agreement |
Loading...
